In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on CytomX Therapeutics, with a price target of $10.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mitchell Kapoor’s rating is based on the potential of CytomX Therapeutics’ CX-2051 to deliver impressive results in the treatment of colorectal cancer. The analysis highlights several scenarios, with the most optimistic one showing a high objective response rate (ORR) and progression-free survival (mPFS), which could make CX-2051 a competitive option in later lines of therapy.
The interim data has already shown promise, particularly in patients pretreated with irinotecan, and even a moderate success in upcoming data could significantly outperform current treatments. The analysis also notes the importance of managing side effects like Grade 3 diarrhea, which could influence the drug’s adoption and commercial success. Overall, the potential for CX-2051 to exceed current standards in 4L treatment and possibly challenge 3L options supports a Buy rating.
In another report released on November 20, Cantor Fitzgerald also maintained a Buy rating on the stock with a $6.00 price target.